To outcompete China, unhandcuff America’s biotech innovators
The Hill · C · trust 42/100
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
Read the original at The Hill →
Open in TruthVane →